JP2010500370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500370A5 JP2010500370A5 JP2009523966A JP2009523966A JP2010500370A5 JP 2010500370 A5 JP2010500370 A5 JP 2010500370A5 JP 2009523966 A JP2009523966 A JP 2009523966A JP 2009523966 A JP2009523966 A JP 2009523966A JP 2010500370 A5 JP2010500370 A5 JP 2010500370A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- huluc63
- ebmt
- administration induces
- remission
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83625006P | 2006-08-07 | 2006-08-07 | |
| US85614406P | 2006-11-01 | 2006-11-01 | |
| PCT/US2007/075401 WO2008019376A2 (en) | 2006-08-07 | 2007-08-07 | Compositions and methods using anti-cs1 antibodies to treat multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013178996A Division JP5775125B2 (ja) | 2006-08-07 | 2013-08-30 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010500370A JP2010500370A (ja) | 2010-01-07 |
| JP2010500370A5 true JP2010500370A5 (enExample) | 2010-09-30 |
Family
ID=39033619
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523966A Withdrawn JP2010500370A (ja) | 2006-08-07 | 2007-08-07 | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| JP2013178996A Active JP5775125B2 (ja) | 2006-08-07 | 2013-08-30 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
| JP2015074786A Active JP6005205B2 (ja) | 2006-08-07 | 2015-04-01 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
| JP2016172453A Pending JP2017025077A (ja) | 2006-08-07 | 2016-09-05 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013178996A Active JP5775125B2 (ja) | 2006-08-07 | 2013-08-30 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
| JP2015074786A Active JP6005205B2 (ja) | 2006-08-07 | 2015-04-01 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
| JP2016172453A Pending JP2017025077A (ja) | 2006-08-07 | 2016-09-05 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7842293B2 (enExample) |
| EP (2) | EP2068930B1 (enExample) |
| JP (4) | JP2010500370A (enExample) |
| AU (1) | AU2007281682B2 (enExample) |
| BR (1) | BRPI0716475A2 (enExample) |
| CA (1) | CA2660102C (enExample) |
| CY (1) | CY1113309T1 (enExample) |
| DK (1) | DK2068930T3 (enExample) |
| ES (1) | ES2391790T3 (enExample) |
| HR (1) | HRP20120934T1 (enExample) |
| IL (1) | IL196920A (enExample) |
| MX (1) | MX2009001440A (enExample) |
| NO (1) | NO345083B1 (enExample) |
| NZ (1) | NZ574979A (enExample) |
| PL (1) | PL2068930T3 (enExample) |
| PT (1) | PT2068930E (enExample) |
| WO (1) | WO2008019376A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010500370A (ja) | 2006-08-07 | 2010-01-07 | ピーディーエル バイオファーマ，インコーポレイティド | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| PT2068874E (pt) * | 2006-08-07 | 2015-05-21 | Abbvie Biotherapeutics Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi |
| CN102112147B (zh) | 2008-06-02 | 2014-05-21 | 达纳-法伯癌症研究所股份有限公司 | Xbp1、cd138、和cs1肽 |
| KR20110096536A (ko) | 2008-10-31 | 2011-08-30 | 애보트 바이오테라퓨틱스 코포레이션 | 희귀 림프종의 치료를 위한 항ｃｓ1 항체의 용도 |
| AU2011382454B2 (en) | 2011-11-30 | 2017-02-23 | Abbvie Biotechnology Ltd | Vectors and host cells comprising a modified SV40 promoter for protein expression |
| CA2880896C (en) | 2012-06-26 | 2021-11-16 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| AU2013337247B2 (en) | 2012-11-05 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| US20160264670A1 (en) | 2013-11-06 | 2016-09-15 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| ES2707057T3 (es) | 2013-11-06 | 2019-04-02 | Bristol Myers Squibb Co | Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple |
| JP2017537893A (ja) * | 2014-10-31 | 2017-12-21 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | 抗ｃｓ１抗体および抗体薬結合体 |
| US20170355768A1 (en) | 2014-12-04 | 2017-12-14 | Bristol-Myers Squibb Company | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
| PL3313528T3 (pl) | 2015-06-29 | 2021-12-13 | Bristol-Myers Squibb Company | Schematy dawkowania immunoterapeutycznego obejmujące pomalidomid i przeciwciało anty-cs1 w leczeniu raka |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| JP2022553821A (ja) | 2019-11-05 | 2022-12-26 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍ－タンパク質アッセイおよびその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112969A (en) | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
| JPH11511746A (ja) | 1995-05-25 | 1999-10-12 | バクスター、インターナショナル、インコーポレイテッド | 同種幹細胞移植後の癌の同種細胞治療 |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| JP2010500370A (ja) * | 2006-08-07 | 2010-01-07 | ピーディーエル バイオファーマ，インコーポレイティド | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| EP2069478A2 (en) | 2006-08-07 | 2009-06-17 | PDL BioPharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| PT2068874E (pt) | 2006-08-07 | 2015-05-21 | Abbvie Biotherapeutics Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi |
-
2007
- 2007-08-07 JP JP2009523966A patent/JP2010500370A/ja not_active Withdrawn
- 2007-08-07 MX MX2009001440A patent/MX2009001440A/es active IP Right Grant
- 2007-08-07 PL PL07840744T patent/PL2068930T3/pl unknown
- 2007-08-07 PT PT07840744T patent/PT2068930E/pt unknown
- 2007-08-07 CA CA2660102A patent/CA2660102C/en active Active
- 2007-08-07 WO PCT/US2007/075401 patent/WO2008019376A2/en not_active Ceased
- 2007-08-07 HR HRP20120934TT patent/HRP20120934T1/hr unknown
- 2007-08-07 NZ NZ574979A patent/NZ574979A/en unknown
- 2007-08-07 AU AU2007281682A patent/AU2007281682B2/en active Active
- 2007-08-07 ES ES07840744T patent/ES2391790T3/es active Active
- 2007-08-07 US US11/835,245 patent/US7842293B2/en active Active
- 2007-08-07 BR BRPI0716475A patent/BRPI0716475A2/pt not_active Application Discontinuation
- 2007-08-07 EP EP07840744A patent/EP2068930B1/en active Active
- 2007-08-07 EP EP11176209A patent/EP2425849A3/en not_active Withdrawn
- 2007-08-07 DK DK07840744.2T patent/DK2068930T3/da active
-
2009
- 2009-02-05 IL IL196920A patent/IL196920A/en active Protection Beyond IP Right Term
- 2009-03-03 NO NO20090969A patent/NO345083B1/no unknown
-
2010
- 2010-10-12 US US12/903,051 patent/US20110165154A1/en not_active Abandoned
-
2012
- 2012-10-31 CY CY20121101037T patent/CY1113309T1/el unknown
-
2013
- 2013-08-30 JP JP2013178996A patent/JP5775125B2/ja active Active
-
2015
- 2015-04-01 JP JP2015074786A patent/JP6005205B2/ja active Active
-
2016
- 2016-04-06 US US15/091,977 patent/US20160206734A1/en not_active Abandoned
- 2016-09-05 JP JP2016172453A patent/JP2017025077A/ja active Pending